PARP inhibitors

GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
Endpoints
GSK
Zejula
ovarian cancer
FDA
PARP inhibitors
Flag link:
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn
Fierce Pharma
Clovis Oncology
Rubraca
NICE
UK
PARP inhibitors
Flag link:
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Flag link:
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula
Flag link:
AstraZeneca strengthens lead in PARP drug class
AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
Flag link:
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula
Flag link:
ESMO 2019 preview – PARPs on parade
ESMO 2019 preview – PARPs on parade
EP Vantage
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
Flag link:
More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZ
More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZ
Pharmaforum
AstraZeneca
Theragnostics
PARP inhibitors
diagnostics
cancer
Flag link:
Clovis investors lose faith as Rubraca struggles against Big Pharma's marketing giants
Clovis investors lose faith as Rubraca struggles against Big Pharma's marketing giants
Fierce Pharma
Clovis Oncology
Rubraca
PARP inhibitors
Flag link:
Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
Endpoints
AstraZeneca
cediranib
ovarian cancer
Yale
PARP inhibitors
Flag link:
Early pancreatic cancer data give Clovis a new path in PARP market
Early pancreatic cancer data give Clovis a new path in PARP market
Biopharma Dive
pancreatic cancer
Clovis Oncology
AstraZeneca
PARP inhibitors
AACR
Rubraca
Lynparza
Flag link:
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
Xconomy
GSK
M&A
Tesaro
PARP inhibitors
Zejula
AstraZeneca
Flag link:
PARP makers search for a way to break through
PARP makers search for a way to break through
Biopharma Dive
AstraZeneca
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Flag link:
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
Flag link:
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Fierce Pharma
AstraZeneca
Merck
Lynparza
PARP inhibitors
BRCA-mutated ovarian cancer
Flag link:
Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?
Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?
Fierce Pharma
Pfizer
breast cancer
PARP inhibitors
Talzenna
Flag link:
FDA approves Pfizer's drug for advanced breast cancer
FDA approves Pfizer's drug for advanced breast cancer
Reuters
FDA
Pfizer
PARP inhibitors
talazoparib
breast cancer
BRCA-mutant breast cancer
Flag link:
PARP inhibitors show promise for treating ALS and other brain disorders
PARP inhibitors show promise for treating ALS and other brain disorders
Fierce Biotech
PARP inhibitors
AstraZeneca
Lynparza
Tesaro
Zejula
ALS
Flag link:
Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital
Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital
Endpoints
Chian
PARP inhibitors
Lilly Asian Ventures
Flag link:
AstraZeneca Goes Up Against 2 Cancer Upstarts
AstraZeneca Goes Up Against 2 Cancer Upstarts
Motley Fool
AstraZeneca
Clovis Oncology
PARP inhibitors
Lynparza
ovarian cancer
breast cancer
Rubraca
Zejula
Flag link:

Pages